FDA video warning on metoclopramide and tardive dyskinesia
Video: patient safety warning on chronic use of metoclopramide and the risk of developing tardive dyskinesia.
Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory
Raptiva and progressive multifocal leukoencephalopathy : EMEA recommends withdrawal of marketing authorization and FDA recommends monitoring patients.
Xigris (Drotrecogin alfa activated): concerns of serious bleeding and increased death trigger FDA safety review
On February 4th, 2009 the FDA announced an ongoing safety review of Xigris (Drotrecogin alfa [activated]). An introduction from Wikipedia: Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C ( rhAPC) that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class […]